Keratouveitis

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 270 Experts worldwide ranked by ideXlab platform

Francesca Romana Pesci - One of the best experts on this subject based on the ideXlab platform.

  • levofloxacin and tobramycin for severe bacterial Keratouveitis
    Ocular Immunology and Inflammation, 2015
    Co-Authors: Massimo Accorinti, Lorena Colao, Marta Gilardi, Michela Cecere, Alessandra Salotti, Francesca Romana Pesci
    Abstract:

    AbstractPurpose: To report on clinical features and outcome of severe bacterial Keratouveitis.Methods: Twenty patients with severe bacterial Keratouveitis treated with topical tobramycin and levofloxacin and oral levofloxacin were included. Main outcome measures were ulcers location, bacterial isolates, risk factors, visual prognosis.Results: Centrally located ulcer/abscess was present in 65% of patients. Contact lens (CL) wear was the most common risk factor (70%). Bacterial isolates were observed in 58% of patients, none resistant to tobramycin and levofloxacin. Pseudomonas aeruginosa was found in 47% of positive cases and in 64% of CL wearers. After therapy, the mean visual acuity improved significantly (p < 0.0001), particularly in contact lens wearers (p = 0.04) and in patients younger than 60 years old (p < 0.001).Conclusions: Pseudomonas aeruginosa is the most frequent cause of bacterial Keratouveitis and CL wear the most common risk factor. Topical tobramycin and levofloxacin and oral levofloxacin...

  • Levofloxacin and Tobramycin for Severe Bacterial Keratouveitis
    Ocular Immunology and Inflammation, 2015
    Co-Authors: Massimo Accorinti, Lorena Colao, Marta Gilardi, Michela Cecere, Alessandra Salotti, Francesca Romana Pesci
    Abstract:

    AbstractPurpose: To report on clinical features and outcome of severe bacterial Keratouveitis.Methods: Twenty patients with severe bacterial Keratouveitis treated with topical tobramycin and levofloxacin and oral levofloxacin were included. Main outcome measures were ulcers location, bacterial isolates, risk factors, visual prognosis.Results: Centrally located ulcer/abscess was present in 65% of patients. Contact lens (CL) wear was the most common risk factor (70%). Bacterial isolates were observed in 58% of patients, none resistant to tobramycin and levofloxacin. Pseudomonas aeruginosa was found in 47% of positive cases and in 64% of CL wearers. After therapy, the mean visual acuity improved significantly (p 

Marcela Escobargomez - One of the best experts on this subject based on the ideXlab platform.

Massimo Accorinti - One of the best experts on this subject based on the ideXlab platform.

  • levofloxacin and tobramycin for severe bacterial Keratouveitis
    Ocular Immunology and Inflammation, 2015
    Co-Authors: Massimo Accorinti, Lorena Colao, Marta Gilardi, Michela Cecere, Alessandra Salotti, Francesca Romana Pesci
    Abstract:

    AbstractPurpose: To report on clinical features and outcome of severe bacterial Keratouveitis.Methods: Twenty patients with severe bacterial Keratouveitis treated with topical tobramycin and levofloxacin and oral levofloxacin were included. Main outcome measures were ulcers location, bacterial isolates, risk factors, visual prognosis.Results: Centrally located ulcer/abscess was present in 65% of patients. Contact lens (CL) wear was the most common risk factor (70%). Bacterial isolates were observed in 58% of patients, none resistant to tobramycin and levofloxacin. Pseudomonas aeruginosa was found in 47% of positive cases and in 64% of CL wearers. After therapy, the mean visual acuity improved significantly (p < 0.0001), particularly in contact lens wearers (p = 0.04) and in patients younger than 60 years old (p < 0.001).Conclusions: Pseudomonas aeruginosa is the most frequent cause of bacterial Keratouveitis and CL wear the most common risk factor. Topical tobramycin and levofloxacin and oral levofloxacin...

  • Levofloxacin and Tobramycin for Severe Bacterial Keratouveitis
    Ocular Immunology and Inflammation, 2015
    Co-Authors: Massimo Accorinti, Lorena Colao, Marta Gilardi, Michela Cecere, Alessandra Salotti, Francesca Romana Pesci
    Abstract:

    AbstractPurpose: To report on clinical features and outcome of severe bacterial Keratouveitis.Methods: Twenty patients with severe bacterial Keratouveitis treated with topical tobramycin and levofloxacin and oral levofloxacin were included. Main outcome measures were ulcers location, bacterial isolates, risk factors, visual prognosis.Results: Centrally located ulcer/abscess was present in 65% of patients. Contact lens (CL) wear was the most common risk factor (70%). Bacterial isolates were observed in 58% of patients, none resistant to tobramycin and levofloxacin. Pseudomonas aeruginosa was found in 47% of positive cases and in 64% of CL wearers. After therapy, the mean visual acuity improved significantly (p 

  • Herpes simplex virus vaccine in recurrent herpetic ocular infection.
    Cornea, 1999
    Co-Authors: Paola Pivetti-pezzi, Massimo Accorinti, Rossella Anna Maria Colabelli-gisoldi, Maria Pia Pirraglia, Maria Caterina Sirianni
    Abstract:

    PURPOSE: To evaluate the efficacy of an antiherpetic vaccine in recurrent herpetic ocular infections. METHODS: Twenty patients with herpes simplex virus 1-related recurrent keratitis/Keratouveitis were prospectively enrolled and randomly assigned to receive either a specific vaccination with heat shock-inactivated herpes simplex virus type 1 (10 patients) or to be observed as controls (10 patients). The number, duration, and anatomic localization of relapses were recorded in all the patients for 12 months before inclusion in the study and for a similar period after the assignment of each subject to vaccine or control group. RESULTS: In the vaccine group, we observed a reduction both in the number (p = 0.016) and average duration (p = 0.050) of recurrences, whereas in the control group, no significant change was found comparing a 12-month period before and after inclusion in the study. The comparison between the two groups highlighted a significant reduction in the number (p = 0.013) and average duration (p = 0.051) of relapses in treated subjects, who did not show any significant vaccine-induced side effects. CONCLUSION: The use of a vaccination with heat shock-inactivated herpes simplex virus 1 seems to be able to reduce the number and duration of relapses in herpes simplex virus 1-related keratitis/Keratouveitis.

Cynthia S Chiu - One of the best experts on this subject based on the ideXlab platform.

  • herpes zoster Keratouveitis and inflammatory ocular hypertension 8 years after varicella vaccination
    Ocular Immunology and Inflammation, 2009
    Co-Authors: Michael K Yoon, Cynthia S Chiu
    Abstract:

    More than 8 years after varicella vaccination, a healthy 16 year-old boy presented with Keratouveitis, severe inflammatory glaucoma in his left eye, and Hutchinson's sign. He was treated with systemic acyclovir, topical steroids, cycloplegics, and glaucoma medications for a full recovery two months after presentation. It is unclear whether the source of herpes zoster which reactivated in this patient represents wild type virus or his previous vaccine strain. Herpes zoster ophthalmicus is very rare in the pediatric population after varicella vaccination but can cause severe inflammatory glaucoma that requires aggressive therapy.

Stella N Arthur - One of the best experts on this subject based on the ideXlab platform.